We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 46

CETA and Canadian IP law: Possible changes ahead?
  • Gowling WLG
  • Canada, European Union
  • March 3 2016

In 2013, an agreement in principle was reached between Canada and the European Union - theCanada-European Union Comprehensive Economic and Trade


Time for change? Potential impact of Canada’s trade negotiations on pharma patents
  • Gowling WLG
  • Canada
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this


Janssen-Ortho v. Apotex, recusal by the judge, levofloxacin, June 14, 2010; motion to dismiss granted, levofloxacin, June 29, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

In a PMNOC case, Justice Shore granted an order of prohibition against Apotex in respect of its levofloxacin until patent expiry


Pfizer v Ratiopharm, PMNOC Regulations decision, sildenafil citrate, June 8, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

The Court dismissed an application for an order of prohibition under the PMNOC Regulations, wherein ratiopharm sought a generic version of the drug Revatio containing sildenafil citrate (the active ingredient in Viagra) until after the expiry of a Pfizer patent


Astrazeneca v. Apotex, PMNOC Regulations decision, esomeprazole, June 30, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

The court dismissed AstraZeneca's application AstraZeneca for an order prohibiting the issuance of a Notice of Compliance ("NOC") to Apotex on the grounds that the allegation of invalidity was justified insofar as the assertions of lack of utilitysound prediction and obviousness, but not justified regarding an assertion of anticipation


Apotex v. Pfizer, motion to strike part of a defence pertaining to res judicata, sildenafil citrate, June 11, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

Apotex applied to impeach Pfizer's patent for Viagra and Pfizer defended alleging, in part, res judicata


Apotex v Syntex and Roche, dismissal of appeal concerning section 8 of PMNOC Regulations, naproxen, June 10, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

Apotex had sued Roche for damages pursuant to s. 8 of the PMNOC Regulations


Novopharm v. The Minister of Health, motion for a confidentiality order in a judicial review application of decision of Minister of Health, drug name confidential, May 26, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

The Minister decided that before a NOC could be issued to Novopharm, Novopharm must address a specific patent on the Patent Register


Pfizer v. Novopharm, appeal of decision of prothonotary to deny Novopharm’s motion for confidentiality in PMNOC Regulations case, pregabalin, June 21, 2010
  • Gowling WLG
  • Canada
  • July 16 2010

Novopharm served a NOA on Pfizer which it had unilaterally designated confidential


AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case
  • Gowling WLG
  • Canada
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing